UK Votes To Leave The EU – Where Next For The Life Sciences?
This article was originally published in Clinica
So that's it. After months of discussion, debate, and an ocean of statistics, claims and counter-claims, the UK has voted to leave the EU and strike out on its own. It was always going to be a close-run thing, and even on the day of the referendum itself the result seemed too close to call, even if the markets had been rallying in expectation of a Remain vote.
You may also be interested in...
France is exploring the use of hydroxychloroquine and lopinavir/ritonavir in COVID-19, but only in hospitalized patients and in clinical trials, and has banned all exports of the products to avoid possible shortages.
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.